Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.
Citation: Anmol Kumar, Ajay Kumar Gupta, Prashant Kumar Singh. Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease[J]. AIMS Neuroscience, 2024, 11(3): 312-340. doi: 10.3934/Neuroscience.2024020
Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.
| [1] |
Simon DK, Tanner CM, Brundin P (2020) Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med 36: 1-12. https://doi.org/10.1016/j.cger.2019.08.002 
|
| [2] | Fang JY (2022) Parkinson disease. Primer on the Autonomic Nervous System, Fourth Edition.Academic Press 549-552. https://doi.org/10.1016/B978-0-323-85492-4.00061-2 |
| [3] |
Lewis PA (2012) James Parkinson: The man behind the Shaking Palsy. J Parkinsons Dis 2: 181-187. https://doi.org/10.3233/JPD-2012-012108
|
| [4] | Francis S, Medical E (1964) James Parkinson. Med Sci 15: 95. |
| [5] |
Saini N, Singh N, Kaur N, et al. (2024) Motor and non-motor symptoms, drugs, and their mode of action in Parkinson's disease (PD): a review. Med Chem Res 33: 580-599. https://doi.org/10.1007/s00044-024-03203-5
|
| [6] |
van Wamelen DJ, Martinez-Martin P, Weintraub D, et al. (2021) The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. Acta Neurol Scand 143: 3-12. https://doi.org/10.1111/ane.13336
|
| [7] |
Rodriguez-Sanchez F, Rodriguez-Blazquez C, Bielza C, et al. (2021) Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. Sci Rep 11: 23645. https://doi.org/10.1038/s41598-021-03118-w
|
| [8] | World Health OrganizationParkinson disease (2023). Available from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease |
| [9] |
Ou Z, Pan J, Tang S, et al. (2021) Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. Front Public Heal 9: 776847. https://doi.org/10.3389/fpubh.2021.776847
|
| [10] |
Arun M, Thomas PT, Kamble NL, et al. (2023) Disability Certification for Parkinson's Disease in India: Challenges and the Way Forward. Indian J Community Med 48: 639-640. https://doi.org/10.4103/ijcm.ijcm_972_22
|
| [11] |
Ball N, Teo WP, Chandra S, et al. (2019) Parkinson's disease and the environment. Front Neurol 10: 421551. https://doi.org/10.3389/fneur.2019.00218
|
| [12] |
Clarimón J (2020) Genetic-environmental factors finally assessed together in Parkinson's disease. J Neurol Neurosurg Psychiatry 91: 1030. https://doi.org/10.1136/jnnp-2020-324472
|
| [13] |
Periñán MT, Brolin K, Bandres-Ciga S, et al. (2022) Effect Modification between Genes and Environment and Parkinson's Disease Risk. Ann Neurol 92: 715-724. https://doi.org/10.1002/ana.26467
|
| [14] |
Li W, Fu YH, Halliday GM, et al. (2021) PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson's Disease. Front Cell Dev Biol 9: 612476. https://doi.org/10.3389/fcell.2021.612476
|
| [15] | Parkinson's Foundation. New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson's Disease by 2030. Available from: https://www.parkinson.org/about-us/news/parkinsons-prevalence-project |
| [16] |
Fields CR, Bengoa-Vergniory N, Wade-Martins R (2019) Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci 12. https://doi.org/10.3389/fnmol.2019.00299
|
| [17] | Saramowicz K, Siwecka N, Galita G, et al. (2024) Alpha-Synuclein Contribution to Neuronal and Glial Damage in Parkinson's Disease. Int J Mol Sci 25. https://doi.org/10.3390/ijms25010360 |
| [18] |
Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508: 1-12. https://doi.org/10.1016/j.abb.2010.12.017
|
| [19] | Harsing LG (2008) Dopamine and the Dopaminergic Systems of the Brain. Handbook of Neurochemistry and Molecular Neurobiology. Boston, MA: Springer. https://doi.org/10.1007/978-0-387-30382-6_7 |
| [20] |
Klein MO, Battagello DS, Cardoso AR, et al. (2019) Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol Neurobiol 39: 31-59. https://doi.org/10.1007/s10571-018-0632-3
|
| [21] |
Brücke T, Brücke C (2022) Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders. J Neural Transm 129: 581-594. https://doi.org/10.1007/s00702-021-02452-7
|
| [22] |
Lin MK, Farrer MJ (2014) Genetics and genomics of Parkinson's disease. Genome Med 6: 1-16. https://doi.org/10.1186/gm566
|
| [23] |
Sayyaed A, Saraswat N, Vyawahare N, et al. (2023) A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson's disease with insights into screening models. Bull Natl Res Cent 47. https://doi.org/10.1186/s42269-023-01047-4
|
| [24] |
Day JO, Mullin S (2021) The genetics of parkinson's disease and implications for clinical practice. Genes (Basel) 12: 1006. https://doi.org/10.3390/genes12071006
|
| [25] |
Funayama M, Nishioka K, Li Y, et al. (2023) Molecular genetics of Parkinson's disease: Contributions and global trends. J Hum Genet 68: 125-130. https://doi.org/10.1038/s10038-022-01058-5
|
| [26] |
Trinh J, Zeldenrust FMJ, Huang J, et al. (2018) Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33: 1857-1870. https://doi.org/10.1002/mds.27527
|
| [27] |
Lehrer S, Rheinstein PH (2022) α-synuclein enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis. J Proteins Proteomics 13: 109-115. https://doi.org/10.1007/s42485-022-00088-z
|
| [28] |
Calabresi P, Di Lazzaro G, Marino G, et al. (2023) Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease. Brain 146: 3587-3597. https://doi.org/10.1093/brain/awad150
|
| [29] |
Srinivasan E, Chandrasekhar G, Chandrasekar P, et al. (2021) Alpha-Synuclein Aggregation in Parkinson's Disease. Front Med 8: 736978. https://doi.org/10.3389/fmed.2021.736978
|
| [30] | Wang YN, Shi XY, Yin YP, et al. (2024) Association Between Neuroinflammation and Parkinson's Disease: A Comprehensive Mendelian Randomization Study. Mol Neurobiol . https://doi.org/10.1007/s12035-024-04197-2 |
| [31] |
Arena G, Sharma K, Agyeah G, et al. (2022) Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop. Curr Neurol Neurosci Rep 22: 427-440. https://doi.org/10.1007/s11910-022-01207-5
|
| [32] |
Lee Y, Lee S, Chang SC, et al. (2019) Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention. Arch Pharmacal Res 42: 416-425. https://doi.org/10.1007/s12272-019-01133-0
|
| [33] |
Perez RG (2020) Editorial: The Protein Alpha-Synuclein: Its Normal Role (in Neurons) and Its Role in Disease. Front Neurosci 14: 528856. https://doi.org/10.3389/fnins.2020.00116
|
| [34] |
Tonda-Turo C, Origlia N, Mattu C, et al. (2018) Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers. Curr Med Chem 25: 5755-5771. https://doi.org/10.2174/0929867325666180221125759
|
| [35] | Pardo-Moreno T, García-Morales V, Suleiman-Martos S, et al. (2023) Current Treatments and New, Tentative Therapies for Parkinson's Disease. Pharm 15: 770. https://doi.org/10.3390/pharmaceutics15030770 |
| [36] |
Stoker TB, Torsney KM, Barker RA (2018) Emerging treatment approaches for Parkinson's disease. Front Neurosci 12: 419092. https://doi.org/10.3389/fnins.2018.00693
|
| [37] |
Kola S, Subramanian I (2023) Updates in Parkinson's Disease Integrative Therapies: an Evidence-Based Review. Curr Neurol Neurosci Rep 23: 717-726. https://doi.org/10.1007/s11910-023-01312-z
|
| [38] |
Serva SN, Bernstein J, Thompson JA, et al. (2022) An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation. Front Surg 9: 863921. https://doi.org/10.3389/fsurg.2022.863921
|
| [39] |
Lee ESY, Chen H, King J, et al. (2008) The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res 33: 401-411. https://doi.org/10.1007/s11064-007-9442-6
|
| [40] |
Li W, Zheng M, Wu S, et al. (2017) Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res 36: 1-12. https://doi.org/10.1186/s13046-017-0530-4
|
| [41] |
Hollingworth SA, McGuire TM, Pache D, et al. (2015) Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. Drugs - Real World Outcomes 2: 199-203. https://doi.org/10.1007/s40801-015-0028-3
|
| [42] |
Jost WH (2022) A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. J Neural Transm 129: 723-736. https://doi.org/10.1007/s00702-022-02465-w
|
| [43] |
Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59: 1233-1250. https://doi.org/10.2165/00003495-200059060-00004
|
| [44] |
Laatikainen O, Sneck S, Turpeinen M (2022) Medication-related adverse events in health care—what have we learned? A narrative overview of the current knowledge. Eur J Clin Pharmacol 78: 159. https://doi.org/10.1007/s00228-021-03213-x
|
| [45] |
Chen JF, Cunha RA (2020) The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. Purinergic Signal 16: 167-174. https://doi.org/10.1007/s11302-020-09694-2
|
| [46] |
Vanegas-Arroyave N, Caroff SN, Citrome L, et al. (2024) An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders. CNS Drugs 38: 239-254. https://doi.org/10.1007/s40263-024-01078-z
|
| [47] |
Church DS, Church MK (2011) Pharmacology of Antihistamines. World Allergy Organ J 4: S22-S27. https://doi.org/10.1186/1939-4551-4-S3-S22
|
| [48] |
Ntetsika T, Papathoma PE, Markaki I (2021) Novel targeted therapies for Parkinson's disease. Mol Med 27: 1-20. https://doi.org/10.1186/s10020-021-00279-2
|
| [49] | Bougea A (2024) Some Novel Therapies in Parkinson's Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomed 12: 549. https://doi.org/10.3390/biomedicines12030549 |
| [50] | Okun MS, Hickey PT, Machado AG, et al. (2022) Temporally optimized patterned stimulation (TOPS®) as a therapy to personalize deep brain stimulation treatment of Parkinson's disease. Front Hum Neurosci 16. https://doi.org/10.3389/fnhum.2022.929509 |
| [51] |
Lewis S, Radcliffe E, Ojemann S, et al. (2024) Pilot Study to Investigate the Use of In-Clinic Sensing to Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease. Neuromodulation 27: 509-519. https://doi.org/10.1016/j.neurom.2023.01.006
|
| [52] | Rossi M, Cerquetti D, Mandolesi J, et al. (2016) Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease. Park Dis Curr Futur Ther Clin Trials : 175-186. |
| [53] |
Hamel W, Köppen JA, Müller D, et al. (2019) The pioneering and unknown stereotactic approach of roeder and orthner from Göttingen. Part II: Long-Term Outcome and Postmortem Analysis of Bilateral Pallidotomy in the Pre-Levodopa Era. Stereotact Funct Neurosurg 96: 353-363. https://doi.org/10.1159/000495412
|
| [54] |
Sharma VD, Patel M, Miocinovic S (2020) Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches. Neurotherapeutics 17: 1525-1538. https://doi.org/10.1007/s13311-020-00939-x
|
| [55] |
Bhansali AP, Gwinn RP (2020) Ablation: Radiofrequency, Laser, and HIFU. Stereotactic and Functional Neurosurgery. Cham: Springer 223-233. https://doi.org/10.1007/978-3-030-34906-6_16
|
| [56] |
Intemann PM, Masterman D, Subramanian I, et al. (2001) Staged bilateral pallidotomy for treatment of Parkinson disease. J Neurosurg 94: 437-444. https://doi.org/10.3171/jns.2001.94.3.0437
|
| [57] |
Franzini A, Moosa S, Servello D, et al. (2019) Ablative brain surgery: an overview. Int J Hyperth 36: 64-80. https://doi.org/10.1080/02656736.2019.1616833
|
| [58] |
Kostiuk K (2023) Stereotactic Staged Asymmetric Bilateral Radiofrequency Lesioning for Parkinson's Disease. Stereotact Funct Neurosurg 101: 359-368. https://doi.org/10.1159/000534084
|
| [59] |
Aradi SD, Hauser RA (2020) Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurother 17: 1339-1365. https://doi.org/10.1007/s13311-020-00889-4
|
| [60] | Chaudhuri KR, Kovács N, Pontieri FE, et al. (2023) Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results. J Parkinsons Dis 13. https://doi.org/10.3233/JPD-225105 |
| [61] |
Fasano A, García-Ramos R, Gurevich T, et al. (2023) Levodopa–carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS. J Neurol 270: 2765-2775. https://doi.org/10.1007/s00415-023-11615-3
|
| [62] |
Baek H, Lockwood D, Mason EJ, et al. (2022) Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders. Front Neurol 13: 880814. https://doi.org/10.3389/fneur.2022.880814
|
| [63] |
Meng Y, Hynynen K, Lipsman N (2020) Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat Rev Neurol 17: 7-22. https://doi.org/10.1038/s41582-020-00418-z
|
| [64] |
Pandey SK, Singh RK (2022) Recent developments in nucleic acid-based therapies for Parkinson's disease: Current status, clinical potential, and future strategies. Front Pharmacol 13: 986668. https://doi.org/10.3389/fphar.2022.986668
|
| [65] | Dumbhare O, Gaurkar SS (2023) A Review of Genetic and Gene Therapy for Parkinson's Disease. Cureus 15: e34657. https://doi.org/10.7759/cureus.34657 |
| [66] |
Jamebozorgi K, Taghizadeh E, Rostami D, et al. (2019) Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Mol Neurobiol 56: 4799-4811. https://doi.org/10.1007/s12035-018-1419-8
|
| [67] | Galetta S, Ganesh A, Lewis A, et al. (2022) Editors' Note: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes from the PD-1101 Trial. Neurology 99: 258. https://doi.org/10.1212/WNL.0000000000201001 |
| [68] |
Paccosi E, Proietti-De-Santis L (2023) Parkinson's Disease: From Genetics and Epigenetics to Treatment, a miRNA-Based Strategy. Int J Mol Sci 24: 9547. https://doi.org/10.3390/ijms24119547
|
| [69] | Panda S, Chatterjee O, Chatterjee S (2023) Nucleic Acid-Based Strategies to Treat Neurodegenerative Diseases. Nucleic Acid Biol its Appl Hum Dis 105–133. https://doi.org/10.1007/978-981-19-8520-1_4 |
| [70] |
Burbulla LF, Zheng J, Song P, et al. (2021) Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models. JCI Insight 6. https://doi.org/10.1172/jci.insight.148649
|
| [71] |
Pinjala P, Tryphena KP, Prasad R, et al. (2023) CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease. Biomater Res 27. https://doi.org/10.1186/s40824-023-00381-y
|
| [72] |
Zafar F, Valappil RA, Kim S, et al. (2018) Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. npj Parkinson's Disease 4: 18. https://doi.org/10.1038/s41531-018-0054-4
|
| [73] | Ho Yoon H, Ye S, Lim S, et al. (2020) CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson's disease. bioRxiv . https://doi.org/10.1101/2020.08.27.269522 |
| [74] | Flores-Fernandez JM, Pesch V, Sriraman A, et al. (2023) Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders. bioRxiv . https://doi.org/10.1101/2023.06.30.547254 |
| [75] |
Duwa R, Jeong JH, Yook S (2021) Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson's disease. J Pharm Investig 51: 465-481. https://doi.org/10.1007/s40005-021-00521-3
|
| [76] |
Antonini A, Bravi D, Sandre M, et al. (2020) Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. Expert Opin Investig Drugs 29: 685-695. https://doi.org/10.1080/13543784.2020.1771693
|
| [77] | Jamal F (2020) Immunotherapies Targeting α-Synuclein in Parkinson Disease. Fed Pract 37: 375-379. https://doi.org/10.12788/fp.0026 |
| [78] |
Nimmo JT, Smith H, Wang CY, et al. (2022) Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta Neuropathol 143: 55-73. https://doi.org/10.1007/s00401-021-02381-5
|
| [79] | Folke J, Ferreira N, Brudek T, et al. (2022) Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomol 12: 168. https://doi.org/10.3390/biom12020168 |
| [80] | TAK-341 | ALZFORUM. Available from: https://www.alzforum.org/therapeutics/tak-341 |
| [81] |
Al-Tuwairqi SM, Badrah AA (2023) Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy. AIMS Math 8: 1800-1832. https://doi.org/10.3934/math.2023093
|
| [82] |
Knecht L, Folke J, Dodel R, et al. (2022) Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective. Neurotherapeutics 19: 1489-1502. https://doi.org/10.1007/s13311-022-01288-7
|
| [83] | Prasinezumab Failure in Parkinson's Phase 2 Trial Detailed | Further Study Underway of Antibody Targeting Alpha-synuclein | Parkinson's News Today. Available from: https://parkinsonsnewstoday.com/news/prasinezumab-failure-parkinsons-phase-2-trial-detailed/ |
| [84] | Stefanis L (2012) α-Synuclein in Parkinson's disease. CSH Perspect Med 2: a009399. https://doi.org/10.1101/cshperspect.a009399 |
| [85] |
Pagano G, Taylor KI, Anzures-Cabrera J, et al. (2022) Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med 387: 421-432. https://doi.org/10.1056/NEJMoa2202867
|
| [86] |
Wang F, Sun Z, Peng D, et al. (2023) Cell-therapy for Parkinson's disease: a systematic review and meta-analysis. J Transl Med 21: 1-22. https://doi.org/10.1186/s12967-023-04484-x
|
| [87] |
Liu Z, Cheung HH (2020) Stem Cell-Based Therapies for Parkinson Disease. Int J Mol Sci 21: 8060. https://doi.org/10.3390/ijms21218060
|
| [88] |
Morizane A (2023) Cell therapy for Parkinson's disease with induced pluripotent stem cells. Inflamm Regen 43: 1-5. https://doi.org/10.1186/s41232-023-00269-3
|
| [89] |
Nasrolahi A, Shabani Z, Sadigh-Eteghad S, et al. (2024) Stem Cell Therapy for the Treatment of Parkinson's Disease: What PromiseDoes it Hold?. Curr Stem Cell Res Ther 19: 185-199. https://doi.org/10.2174/1574888X18666230222144116
|
| [90] | Gautam A, Bali S (2023) Role of Ai in the Diagnosis and Management of Parkinsonism. Int J Med Pharm Res 4: 393-397. |
| [91] | Ouyang A (2022) Artificial intelligence model can detect Parkinson's from breathing patterns. MIT News . Available from: https://news.mit.edu/2022/artificial-intelligence-can-detect-parkinsons-from-breathing-patterns-0822. |
| [92] |
Saravanan S, Ramkumar K, Adalarasu K, et al. (2022) A Systematic Review of Artificial Intelligence (AI) Based Approaches for the Diagnosis of Parkinson's Disease. Arch Comput Methods Eng 29: 3639-3653. https://doi.org/10.1007/s11831-022-09710-1
|
| [93] | Dixit S, Bohre K, Singh Y, et al. (2023) A Comprehensive Review on AI-Enabled Models for Parkinson's Disease Diagnosis. Electron 12. https://doi.org/10.3390/electronics12040783 |
| [94] |
McFarthing K, Buff S, Rafaloff G, et al. (2023) Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. J Parkinsons Dis 13: 427-439. https://doi.org/10.3233/JPD-239901
|
| [95] |
Enogieru AB, Haylett W, Hiss DC, et al. (2018) Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders. Oxid Med Cell Longev : 6241017. https://doi.org/10.1155/2018/6241017
|
| [96] |
Hauser RA, Giladi N, Poewe W, et al. (2022) P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Adv Ther 39: 1881-1894. https://doi.org/10.1007/s12325-022-02097-2
|
| [97] |
Bette S, Shpiner DS, Singer C, et al. (2018) Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag 14: 1737. https://doi.org/10.2147/TCRM.S139545
|
| [98] |
Mertsalmi TH, Pekkonen E, Scheperjans F (2020) Antibiotic exposure and risk of Parkinson's disease in Finland: A nationwide case-control study. Mov Disord 35: 431-442. https://doi.org/10.1002/mds.27924
|
| [99] |
Nakamori M, Junn E, Mochizuki H, et al. (2019) Nucleic Acid-Based Therapeutics for Parkinson's Disease. Neurotherapeutics 16: 287-298. https://doi.org/10.1007/s13311-019-00714-7
|
| [100] |
Brandacher G, Perathoner A, Ladurner R, et al. (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin Cancer Res 12: 1144-1151. https://doi.org/10.1158/1078-0432.CCR-05-1966
|
| [101] | WO2012075473A1 - Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters - Google Patents. Available from: https://patents.google.com/patent/WO2012075473A1/en17 |
| [102] |
Kolwicz SC, Olson DP, Marney LC, et al. (2019) ACC inhibitors and uses thereof. Circ Res 111: 728-738. https://doi.org/10.1161/CIRCRESAHA.112.268128
|
| [103] | Michael E. Bozik, Thomas Petzinger, Jr., Valentin Gribkoff, Inventors; Knopp Neurosciences, Inc. Assignee. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same. Google Patents US8524695B2. 2013 Sep. 3. Available from: https://patents.google.com/patent/US8524695B2/en?oq=US8524695B2 |
| [104] | JP6556146B2 - Heterocyclic compounds - Google Patents. Available from: https://patents.google.com/patent/JP6556146B2/en?oq=JP6556146B2 |
| [105] | ES2723876T3 - New pyrazole derivatives - Google Patents. Available from: https://patents.google.com/patent/ES2723876T3/en?oq=ES2723876T3 |
| [106] | CN109125261B - Edaravone dosage form - Google Patents. Available from: https://patents.google.com/patent/CN109125261B/en?oq=CN109125261B |
| [107] | Administration TD, Insuline OD, Soir LE Tepzz_59 4￥8b_t (11) (2014)1: 1-31. |
| [108] | JP2018118914A - Pharmaceutical for ameliorating neurodegenerative diseases - Google Patents. Available from: https://patents.google.com/patent/JP2018118914A/en?oq=JP2018118914A |
| [109] | CA2806444C - Prodrugs of methyl hydrogen fumarate - Google Patents. Available from: https://patents.google.com/patent/CA2806444C/en?oq=16.CA2806444CMethyl+Hydrogen+Fumarate+(MHF)+Immunomodulation+inhibits+inflammatory+mediators+and+interaction+with+the+TNF+signaling+pathways.23%2F02%2F201619%2F08%2F2029 |
| [110] | CN102755310B - A kind of composition medicine preparation containing levodopa - Google Patents. Available from: https://patents.google.com/patent/CN102755310B/en?oq=CN102755310B |
| [111] | JP7443606B2 - Novel catecholamine prodrugs for use in the treatment of Parkinson's disease - Google Patents. Available from: https://patents.google.com/patent/JP7443606B2/en?oq=18.JP7443606B2(4aR%2C+10aR)-1-n-propyl-1%2C2%2C3%2C4%2C4a%2C5%2C10%2C10a-octahydro-benzo[g]quinoline-6%2C7-diolDopamine+agonist%2C+provides+dopaminergic+innervation+to+the+striatum+and+other+brain+regions%2C+ultimately+affecting+the+basal+ganglia+circuitry05%2F03%2F202423%2F11%2F2038 |
| [112] | JP6251259B2 - Novel 5-aminotetrahydroquinoline-2-carboxylic acid and use thereof - Google Patents. Available from: https://patents.google.com/patent/JP6251259B2/en?oq=19.JP6251259B25-amino-5%2C6%2C7%2C8-tetrahydroquinoline-2-carboxylic+acidSoluble+guanylate+cyclase+(sGC)+activator%2C+stimulating+the+biosynthesis+of+cGMP+from+GTP20%2F12%2F201716%2F07%2F2033 |
Figures(4) / Tables(2)
Anmol Kumar, Ajay Kumar Gupta, Prashant Kumar Singh. Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease[J]. AIMS Neuroscience, 2024, 11(3): 312-340. doi: 10.3934/Neuroscience.2024020
DownLoad: